Article

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Cancer Research UK London Research Institute, London, United Kingdom.
New England Journal of Medicine (Impact Factor: 54.42). 03/2012; 366(10):883-92. DOI: 10.1056/NEJMoa1113205
Source: PubMed

ABSTRACT Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples.
To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple spatially separated samples obtained from primary renal carcinomas and associated metastatic sites. We characterized the consequences of intratumor heterogeneity using immunohistochemical analysis, mutation functional analysis, and profiling of messenger RNA expression.
Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region. Intratumor heterogeneity was observed for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro. Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially separated inactivating mutations within a single tumor, suggesting convergent phenotypic evolution. Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor. Allelic composition and ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors.
Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development. Intratumor heterogeneity, associated with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection. (Funded by the Medical Research Council and others.).

0 Followers
 · 
482 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clonal evolution in cancer-the selection for and emergence of increasingly malignant clones during progression and therapy, resulting in cancer metastasis and relapse-has been highlighted as an important phenomenon in the biology of leukemia and other cancers. Tracking mutant alleles to determine clonality from diagnosis to relapse or from primary site to metastases in a sensitive and quantitative manner is most often performed using next-generation sequencing. Such methods determine clonal frequencies by extrapolation of allele frequencies in sequencing data of DNA from the metagenome of bulk tumor samples using a set of assumptions. The computational framework that is usually used assumes specific patterns in the order of acquisition of unique mutational events and heterozygosity of mutations in single cells. However, these assumptions are not accurate for all mutant loci in acute myeloid leukemia (AML) samples. To assess whether current models of clonal diversity within individual AML samples are appropriate for common mutations, we developed protocols to directly genotype AML single cells. Single-cell analysis demonstrates that mutations of FLT3 and NPM1 occur in both homozygous and heterozygous states, distributed among at least nine distinct clonal populations in all samples analyzed. There appears to be convergent evolution and differential evolutionary trajectories for cells containing mutations at different loci. This work suggests an underlying tumor heterogeneity beyond what is currently understood in AML, which may be important in the development of therapeutic approaches to eliminate leukemic cell burden and control clonal evolution-induced relapse. Copyright © 2015, American Association for the Advancement of Science.
    Science translational medicine 04/2015; 7(281):281re2. DOI:10.1126/scitranslmed.aaa0763 · 14.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The presence of an EGFR activating mutation is predictive of benefit from reversible and irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI) allowing personalized medicine in lung cancer. However, intratumoral heterogeneity in EGFR mutation status has recently been described and ranged from 13.9% to 27% in some studies. Intratumor heterogeneity may have important consequences for personalized-medicine approaches that commonly rely on a single tumor-biopsy to portray tumor mutational landscape. EGFR mutation heterogeneity could also explain the mixed responses phenomenon and act as a mechanism of acquired resistance to EGFR-TKI. In order to a better tailored treatment in advanced non-small cell lung cancer (NSCLC), it is extremely important to elucidate the relevance and degree of heterogeneous distribution of the targeted biomarker regarding the metastasis localisation, previous systemic treatments and interval between primary tumor and metastasis. Additionally, these findings would also help us to design new strategies for patients with lung cancer harboring heterogeneous EGFR mutations.
    12/2013; 2(6):445-8. DOI:10.3978/j.issn.2218-6751.2013.10.14
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Drug combinations can improve angiostatic cancer treatment efficacy and enable the reduction of side effects and drug resistance. Combining drugs is non-trivial due to the high number of possibilities. We applied a feedback system control (FSC) technique with a population-based stochastic search algorithm to navigate through the large parametric space of nine angiostatic drugs at four concentrations to identify optimal low-dose drug combinations. This implied an iterative approach of in vitro testing of endothelial cell viability and algorithm-based analysis. The optimal synergistic drug combination, containing erlotinib, BEZ-235 and RAPTA-C, was reached in a small number of iterations. Final drug combinations showed enhanced endothelial cell specificity and synergistically inhibited proliferation (p < 0.001), but not migration of endothelial cells, and forced enhanced numbers of endothelial cells to undergo apoptosis (p < 0.01). Successful translation of this drug combination was achieved in two preclinical in vivo tumor models. Tumor growth was inhibited synergistically and significantly (p < 0.05 and p < 0.01, respectively) using reduced drug doses as compared to optimal single-drug concentrations. At the applied conditions, single-drug monotherapies had no or negligible activity in these models. We suggest that FSC can be used for rapid identification of effective, reduced dose, multi-drug combinations for the treatment of cancer and other diseases.
    Angiogenesis 03/2015; DOI:10.1007/s10456-015-9462-9 · 4.41 Impact Factor

Full-text

Download
32 Downloads
Available from
Oct 12, 2014